Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Psyence Biomedical Ltd (PBM)

Psyence Biomedical Ltd (PBM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone GlobeNewswire - Wed Mar 11, 8:15AM CDT

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial GlobeNewswire - Tue Mar 3, 8:15AM CST

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment GlobeNewswire - Fri Feb 20, 4:20PM CST

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders GlobeNewswire - Tue Feb 17, 8:15AM CST

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 2.50 (-0.40%)
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway GlobeNewswire - Fri Feb 13, 5:30PM CST

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), a biopharmaceutical company advancing nature-derived psilocybin and...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Settlement of Shareholder Litigation GlobeNewswire - Wed Feb 11, 8:15AM CST

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence BioMed " or the " Company ") today announced that it has entered into a settlement agreement to resolve a...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split GlobeNewswire - Wed Jan 28, 5:30PM CST

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), today announced the effective date of its 1-for-6.25 share consolidation...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 GlobeNewswire - Thu Jan 22, 12:42PM CST

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”) today announced that it adjourned its annual and special meeting of shareholders...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date GlobeNewswire - Tue Jan 20, 6:19AM CST

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced...

PBM : 2.50 (-0.40%)
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split GlobeNewswire - Wed Jan 14, 6:00PM CST

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation...

PBM : 2.50 (-0.40%)

Barchart Exclusives

Should You Buy Vertiv Stock Before March 23? Barchart - 3 minutes ago
Vertiv stock surged to an all-time high on news of its inclusion in the S&P 500. Here's what investors need to know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot